Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Therapeutic intervention by the simultaneous inhibition of DNA repair and type I or type II DNA topoisomerases: one strategy, many outcomes.

Future medicinal chemistry - 1 Jan 2012

Węsierska-Gądek Józefa, Składanowski Andrzej

Abstract excerpt

Many anticancer drugs reduce the integrity of DNA, forming strand breaks. This can cause mutations and cancer or cell death if the lesions are not repaired. Interestingly, DNA repair-deficient cancer cells (e.g., those with BRCA1/2 mutations) have been shown to exhibit increased sensitivity to chemotherapy. Based on this observation, a new therapeutic approach termed 'synthetic lethality' has been developed, in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to DNA Repair
Share to Genes, BRCA1
Share to Genes, BRCA2

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genomic Instability

Share to Mice, Knockout

Share to Topoisomerase I Inhibitors

Share to Topoisomerase II Inhibitors

Source

Identifiers

PMID: 22168164
DOI: 10.4155/fmc.11.175

Genes

BRCA1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Therapeutic intervention by the simultaneous inhibition of DNA repair and type I or type II DNA topoisomerases: one strategy, many outcomes.PMID 22168164Read ↗

Embracing synthetic lethality of novel anticancer therapies.Semantic proximity Read ↗

Synthetic lethality and cancer therapy: lessons learned from the development of PARP inhibitors.Semantic proximity Read ↗

Synthetic lethality: exploiting the addiction of cancer to DNA repair.Semantic proximity Read ↗

PARP inhibitors: Synthetic lethality in the clinicSemantic proximity Read ↗

PARP inhibition as a prototype for synthetic lethal screens.Semantic proximity Read ↗

The synthetic lethality of targeting cell cycle checkpoints and PARPs in cancer treatmentSemantic proximity Read ↗

Molecular Pathways: Targeting PARP in Cancer TreatmentSemantic proximity Read ↗

Poly(ADP-Ribose) polymerase (PARP) inhibitors: Exploiting a synthetic lethal strategy in the clinicSemantic proximity Read ↗

Advances and perspectives of PARP inhibitorsSemantic proximity Read ↗

DNA damage response inhibition‐based combination therapies in cancer treatment: Recent advances and future directionsSemantic proximity Read ↗

Poly(ADP-ribose) polymerase-1 inhibition: preclinical and clinical development of synthetic lethality.Semantic proximity Read ↗

Drugging the Cancers Addicted to DNA RepairSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.